BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
bioAffinity Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.51−0.22 (-5.90%)
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
bioAffinity Technologies, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services [Member] | $5.90M | $5.66M | $6.16M | $6.78M | $7.68M | $8.80M | $9.35M | $9.35M | $7.29M | $4.92M | $2.51M | 100.0% | -23.2% |
| Health Care, Patient Service [Member] | $4.79M | $4.48M | $4.97M | $5.60M | $6.48M | $7.60M | $8.18M | $8.21M | – | – | $2.20M | 81.1% | -26.1% |
| Histology Service Fees [Member] | $1.04M | $1.10M | $1.12M | $1.12M | $1.15M | $1.13M | $1.10M | $1.05M | – | – | $272.66K | 17.7% | -9.0% |
| Medical Director Fees [Member] | $69.38K | $69.14K | $68.27K | $67.61K | $67.28K | $67.11K | $66.58K | – | – | – | – | 1.2% | +3.1% |
| Other Revenues [Member] | $1.33K | $2.20K | $4.86K | – | – | – | – | – | – | – | – | 0.0% | – |
| Diagnostic R&D [Member] | – | – | – | – | – | – | $8.65K | $13.85K | $26.37K | – | $19.44K | – | – |
| Health Care, Other [Member] | – | – | – | – | – | – | – | $67.07K | – | – | $19.32K | – | – |
| Department of Defense Observational Studies [Member] | – | – | – | – | – | – | $8.65K | $13.85K | – | – | $19.44K | – | – |
By region
From the segment and revenue-disaggregation notes of bioAffinity Technologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.